Personalized gene silencing therapeutics for Huntington disease

Clinical Genetics

Volumn 86, Issue 1, 2014, Pages 29-36

  Kay, C ^a   Skotte, N H ^a   Southwell, A L ^a   Hayden, M R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense oligonucleotides; Gene silencing; Haplotypes; Huntington disease; Personalized medicine; Population genetics; Single stranded siRNA; SNPs; Trinucleotide repeat

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; GLUTAMINE; HUNTINGTIN; MICRORNA; OLIGONUCLEOTIDE; RIBONUCLEASE H; SMALL INTERFERING RNA; TRINUCLEOTIDE; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ALLELE; CAG REPEAT; CAUCASIAN; EXON SKIPPING; GENE LINKAGE DISEQUILIBRIUM; GENE SILENCING; GENE THERAPY; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; HUNTINGTON CHOREA; INTRON; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; SAFETY; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT; UNTRANSLATED REGION; DOMINANT GENE; DRUG EFFECTS; GENETICS; HUNTINGTON DISEASE; PROCEDURES; TRENDS;

GENE SILENCING; GENES, DOMINANT; GENETIC THERAPY; GENETICS, POPULATION; HUMANS; HUNTINGTON DISEASE; INDIVIDUALIZED MEDICINE; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84901688904     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12385     Document Type: Review

References (48)

1. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol 2011: 226: 365-379.
2. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010: 50: 259-293.
3. Sibley CR, Seow Y, Wood MJ. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 2010: 18: 466-476.
4. Lima WF, Prakash TP, Murray HM et al. Single-stranded siRNAs activate RNAi in animals. Cell 2012: 150: 883-894.
5. Grimm D, Wang L, Lee JS et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 2010: 120: 3106-3119.
6. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993: 72: 971-983.
7. Walker FO. Huntington's disease. Lancet 2007: 369: 218-228.
8. Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington's disease - neuropathology. Handb Clin Neurol 2011: 100: 83-100.
9. Kremer B, Goldberg P, Andrew SE et al. A Worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994: 330: 1401-1406.
10. Goldberg YP, Kalchman MA, Metzler M et al. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum Mol Genet 1996: 5: 177-185.
11. Graham RK, Slow EJ, Deng Y et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis 2006: 21: 444-455.
12. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000: 101: 57-66.
13. Banez-Coronel M, Porta S, Kagerbauer B et al. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 2012: 8: e1002481.
14. Tartari M, Gissi C, Lo Sardo V et al. Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 2008: 25: 330-338.
15. Shirasaki DI, Greiner ER, Al-Ramahi I et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 2012: 75: 41-57.
16. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010: 90: 905-981.
17. Nasir J, Floresco SB, O'Kusky JR et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995: 81: 811-823.
18. Duyao MP, Auerbach AB, Ryan A et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995: 269: 407-410.
19. Zeitlin S, Liu JP, Chapman DL et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995: 11: 155-163.
20. Auerbach W, Hurlbert MS, Hilditch-Maguire P et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 2001: 10: 2515-2523.
21. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000: 26: 300-306.
22. Leavitt BR, Guttman JA, Hodgson JG et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001: 68: 313.
23. Van Raamsdonk J, Pearson J, Murphy Z et al. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci 2006: 7: 80.
24. Van Raamsdonk JM, Pearson J, Rogers DA et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 2005: 14: 1379-1392.
25. Leavitt BR, van Raamsdonk JM, Shehadeh J et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006: 96: 1121-1129.
26. Yu D, Pendergraff H, Liu J et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012: 150: 895-908.
27. Fiszer A, Mykowska A, Krzyzosiak WJ. Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 2011: 39: 5578-5585.
28. Fiszer A, Olejniczak M, Galka-Marciniak P et al. Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res 2013: 41: 10426-10437.
29. Gagnon KT, Pendergraff HM, Deleavey GF et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry (Mosc) 2010: 49: 10166-10178.
30. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007: 30: 575-621.
31. Semaka A, Kay C, Doty CN et al. High frequency of intermediate alleles on huntington disease-associated haplotypes in British Columbia's general population. Am J Med Genet B Neuropsychiatr Genet 2013: 162: 864-871.
32. Butland S, Devon R, Huang Y et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 2007: 8: 126.
33. Hu J, Matsui M, Gagnon KT et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009: 27: 478-484.
34. Molla M, Delcher A, Sunyaev S et al. Triplet repeat length bias and variation in the human transcriptome. Proc Natl Acad Sci U S A 2009: 106: 17095-17100.
35. van Bilsen PH, Jaspers L, Lombardi MS et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 2008: 19: 710-719.
36. Pfister EL, Kennington L, Straubhaar J et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009: 19: 774-778.
37. Carroll JB, Warby SC, Southwell AL et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011: 19: 2178-2185.
38. Ostergaard ME, Southwell AL, Kordasiewicz H et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 2013: 41: 9634-9650.
39. Southwell AL, Skotte NH, Bennett CF et al. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med 2012: 18: 634-643.
40. Kordasiewicz HB, Stanek LM, Wancewicz EV et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012: 74: 1031-1044.
41. Lombardi MS, Jaspers L, Spronkmans C et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009: 217: 312-319.
42. Warby SC, Montpetit A, Hayden AR et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009: 84: 351-366.
43. Lee J-M, Gillis T, Mysore Jayalakshmi S et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 2012: 90: 434-444.
44. Warby SC, Visscher H, Collins JA et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 2011: 19: 561-566.
45. Baine FK, Kay C, Ketelaar ME et al. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 2013: 21: 1120-1127.
46. Saleem Q, Roy S, Murgood U et al. Molecular analysis of Huntington's disease and linked polymorphisms in the Indian population. Acta Neurol Scand 2003: 108: 281-286.
47. Southwell AL, Warby SC, Carroll JB et al. A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 2013: 22: 18-34.
48. Goemans NM, Tulinius M, van den Akker JT et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011: 364: 1513-1522.